enVVeno Medical Corp
Change company Symbol lookup
Select an option...
NVNO enVVeno Medical Corp
MTBC CareCloud Inc
WRK Westrock Co
SNDX Syndax Pharmaceuticals Inc
SLAMU Slam Corp
SURYY Sumitomo Realty & Development Co Ltd
MKKGY Merck KGaA
DAC Danaos Corp
YY JOYY Inc
MGU Macquarie Global Infrastructure Total Return Fund Inc.
Go

Health Care : Health Care Equipment & Supplies | Small Cap Growth
Company profile

enVVeno Medical Corporation is a med-tech company. The Company is focused on improving the standard of care in the treatment of venous disease. The Company is focused on developing tissue-based solutions that are designed for patients with chronic venous insufficiency (CVI). Its lead product, VenoValve, is a porcine based device being developed to surgically implanted in the deep venous system of the leg to treat severe CVI, including the potential to heal recurring venous leg ulcers. The VenoValve is designed to be implanted into the femoral vein of the patient in an open surgical procedure via a five-to-six-inch incision in the upper thigh. The VenoValve is being evaluated in the surgical anti-reflux venous valve endoprosthesis (SAVVE) United States clinical trial. In addition to the VenoValve, the Company is focused on the development of a second device, enVVe, for the treatment of venous disease.

Closing Price
$4.22
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
25,424
0

Oracle follows Microsoft into healthcare push with Cerner -- is Salesforce next?

8:30 am ET December 21, 2021 (MarketWatch)
Print

By Jeremy C. Owens

Software giants are looking to buy their way into the healthcare business, which has been slow to jump into cloud computing and software

Oracle Corp. on Monday confirmed plans to acquire Cerner Corp. for nearly $30 billion, pushing into the healthcare space a few months after another software giant, Microsoft Corp., made a similar acquisition, leaving analysts to wonder what other software companies will look to buy their way into hospitals.

Oracle (ORCL)agreed to pay $95 a share in cash for Cerner(CERN), for an equity value of $28.3 billion, the richest deal in the software company's long lineage of software purchases. Cerner sells software that helps doctors access and analyze medical records, producing revenue of $5.5 billion in the 2020 calendar year and $4.3 billion in the first three quarters of this year.

"With this acquisition, Oracle's corporate mission expands to assume the responsibility to provide our overworked medical professionals with a new generation of easier-to-use digital tools that enable access to information via a hands-free voice interface to secure cloud applications," Oracle co-founder and Chief Technology Officer Larry Ellison said in a statement Monday morning.

The healthcare industry, one of the largest in the U.S., has been slow to move into cloud software and cloud computing due to complex rules about digital record-keeping involving health information. Software companies have looked to jump into segments that have proved popular with hospitals and other healthcare providers, including Microsoft's(MSFT) nearly $20 billion acquisition earlier this year of Nuance, a software company that has worked with Cerner in the past.

See also: 20 cloud stocks expected to increase sales the most over the next two years

"The conventional wisdom on healthcare is that it's a big vertical, but not one that's adopted or embraced digital technologies as much as some others," Third Bridge Vice President and Global Lead Scott Kessler wrote in an email Monday. "Cleary Oracle with this pending Cerner deal, and Microsoft with its planning purchase of Nuance Communications, which is also very healthcare oriented, see significant potential."

With Microsoft and Oracle already in the game, analysts wonder if another prominent software company, Salesforce.com Inc. (CRM), will be next, though maybe not soon.

"We believe it's only a matter of time until Salesforce looks to broaden its footprint in this space," Stifel analysts wrote late last week, after news of Oracle's interest in Cerner first surfaced. "Given Salesforce's recent M&A moves and commitment to near-term margin expansion, we believe such a move is unlikely to happen until late CY22 or sometime in CY23.

Oracle's next moves could come quicker. The company has been known to buy companies in bunches, including a spree of cloud-focused acquisitions that culminated with the purchase of NetSuite, a reaction to the growing popularity of Salesforce after Oracle downplayed the rise of cloud software.

"It could mark a return to Oracle's days of aggressive acquisition activity during which time the company very effectively rolled-up the legacy client-server application space," the Stifel analysts, who have a "hold" rating and $87 price target on the stock, wrote. "What is different this time is that the sector is in the midst of strong secular growth driven by an architectural shift to the cloud while the mid 2000s was ripe for consolidation given the significant number of inefficiently run application vendors that had hit the growth-wall."

Oracle also could be using the Cerner acquisition to get a toehold in the healthcare industry and convince those customers to use its cloud-computing option. Cloud-computing providers such as Amazon.com Inc.'s (AMZN) Amazon Web Services, Microsoft and Alphabet Inc.'s (GOOGL)(GOOGL)Google see big potential in moving healthcare providers onto their cloud networks when and where the providers can use the technology.

The return of JEDI: Why the sequel to military's cloud contract could cost much more than the $10 billion original

Oracle stock reacted negatively to the news Monday, after falling Friday in reaction to the initial reports of a potential deal. Shares fell 5.2% Monday after declining 6.4% Friday, putting the stock in correction territory -- down 10% or more from a recent high -- after Oracle hit an all-time closing record of $103.65 on Wednesday.

A majority of analysts who track Oracle consider the stock a hold, with 18 of 30 analysts tracked by FactSet giving the stock that rating while eight consider it the equivalent of a "buy" and four rate it the equivalent of a "sell." The average price target as of Monday morning was $103.25.

-Jeremy C. Owens

	

(END) Dow Jones Newswires

December 21, 2021 08:30 ET (13:30 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.